Novelion Therapeutics Supports World Lipodystrophy Day
March 31 2018 - 6:00AM
Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical
company dedicated to developing new standards of care for
individuals living with rare diseases, today recognizes World
Lipodystrophy Day.
Chief Operating Officer Jeff Hackman said, "We are honored to
join together with the patient community in support of World
Lipodystrophy Day, with a goal of increasing awareness of this
serious rare disease. Awareness and education are important
initiatives which help recognition and diagnosis of the
disease.”
Lipodystrophy is a group of rare diseases characterized by a
lack of fat tissue. In some patients, it is genetic, and in others
it may be acquired. It can be characterized by a widespread lack of
fat tissue under the skin (generalized lipodystrophy) or limited
lack of fat tissue (partial lipodystrophy). This loss of fat tissue
causes a deficit in the hormone leptin, leading to some severe
metabolic complications.
“We are passionate about providing support for lipodystrophy
patients and their caregivers, and we advocate tirelessly to
increase understanding of the disease and further research into
lipodystrophy. World Lipodystrophy Day is an important initiative
that increases public awareness to help us achieve these goals on
behalf of patients living with this serious and often unknown
disease,” said Andra Stratton, president and co-founder of
Lipodystrophy United.
“The challenges that patients living with lipodystrophy and
their families face are significant. World Lipodystrophy Day helps
us to raise awareness and understanding so that we can improve
diagnosis and care for those affected by this rare disease
globally,” said Naca Eulalia Perez de Tudela Cánovas, president and
founder of the international organization Association of Families
Affected by Lipodystrophies in Spain, Europe & Latin
America.
To learn more about lipodystrophy, visit
www.lipodystrophyunited.org, www.aelip.es, or
www.lipodystrophy.co.uk.
CONTACT:Novelion Therapeutics Inc.Amanda MurphyDirector,
Investor Relations & Corporate Communications857-242-5024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Apr 2024 to May 2024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From May 2023 to May 2024